Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

INTRODUCTION: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisondi, Paolo, Gottlieb, Alice B., Elewski, Boni, Augustin, Matthias, McBride, Sandy, Tsai, Tsen-Fang, de la Loge, Christine, Fierens, Frederik, López Pinto, José M., Tilt, Nicola, Lebwohl, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823190/
https://www.ncbi.nlm.nih.gov/pubmed/36509889
http://dx.doi.org/10.1007/s13555-022-00861-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823190/
https://www.ncbi.nlm.nih.gov/pubmed/36509889
http://dx.doi.org/10.1007/s13555-022-00861-4

Ejemplares similares